Study of no Pharmacokinetic Interaction Between Rosuvastatin 20mg and Ezetimibe10mg, Fixed Dose vs Individual Components
Status:
Completed
Trial end date:
2018-01-22
Target enrollment:
Participant gender:
Summary
Monocentric study of no pharmacokinetic interaction between rosuvastatin 20 mg and ezetimibe
10 mg. An open design, randomized, single dose with three periods, six sequences and crossed,
in healthy volunteers with fasting conditions, managed in fixed dose combination (Sponsor
Laboratorios Silanes S.A. de C.V.) versus individual components managed by separated
(Crestor®, product of Astrazeneca, S.A. de C.V and Ezetrol®. product of Undra S.A. de C.V.)